Invacare Competitors

Invacare (NYSE:IVC) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares Invacare and Abbott Laboratories' net margins, return on equity and return on assets.

Insider & Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are owned by institutional investors. 3.2% of Invacare shares are owned by insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Invacare and Abbott Laboratories, as provided by MarketBeat.com.

Invacare currently has a consensus target price of $14.00, indicating a potential upside of 41.13%. Abbott Laboratories has a consensus target price of $115.6875, indicating a potential upside of 0.84%. Given Invacare's stronger consensus rating and higher possible upside, research analysts clearly believe Invacare is more favorable than Abbott Laboratories.

Risk & Volatility

Invacare has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Valuation & Earnings

This table compares Invacare and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Abbott Laboratories beats Invacare on 9 of the 14 factors compared between the two stocks.

Invacare (NYSE:IVC) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares Invacare and Medtronic's net margins, return on equity and return on assets.

Risk & Volatility

Invacare has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Insider & Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 79.2% of Medtronic shares are owned by institutional investors. 3.2% of Invacare shares are owned by insiders. Comparatively, 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Invacare and Medtronic, as provided by MarketBeat.com.

Invacare currently has a consensus target price of $14.00, indicating a potential upside of 41.13%. Medtronic has a consensus target price of $122.2963, indicating a potential upside of 4.62%. Given Invacare's stronger consensus rating and higher possible upside, research analysts clearly believe Invacare is more favorable than Medtronic.

Valuation & Earnings

This table compares Invacare and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Summary

Medtronic beats Invacare on 10 of the 15 factors compared between the two stocks.

Invacare (NYSE:IVC) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Invacare and Stryker's net margins, return on equity and return on assets.

Volatility & Risk

Invacare has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Insider and Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 71.5% of Stryker shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Invacare and Stryker, as provided by MarketBeat.

Invacare currently has a consensus target price of $14.00, indicating a potential upside of 41.13%. Stryker has a consensus target price of $227.4783, indicating a potential downside of 5.04%. Given Invacare's stronger consensus rating and higher possible upside, equities analysts plainly believe Invacare is more favorable than Stryker.

Valuation and Earnings

This table compares Invacare and Stryker's top-line revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Invacare on 11 of the 15 factors compared between the two stocks.

Invacare (NYSE:IVC) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Invacare and Intuitive Surgical's net margins, return on equity and return on assets.

Volatility & Risk

Invacare has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Invacare and Intuitive Surgical, as provided by MarketBeat.

Invacare currently has a consensus target price of $14.00, indicating a potential upside of 41.13%. Intuitive Surgical has a consensus target price of $736.0588, indicating a potential downside of 2.12%. Given Invacare's stronger consensus rating and higher possible upside, equities analysts plainly believe Invacare is more favorable than Intuitive Surgical.

Valuation and Earnings

This table compares Invacare and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Invacare on 10 of the 14 factors compared between the two stocks.

Invacare (NYSE:IVC) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Invacare and Becton, Dickinson and's net margins, return on equity and return on assets.

Volatility & Risk

Invacare has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Invacare and Becton, Dickinson and, as provided by MarketBeat.

Invacare currently has a consensus target price of $14.00, indicating a potential upside of 41.13%. Becton, Dickinson and has a consensus target price of $279.6667, indicating a potential upside of 7.46%. Given Invacare's stronger consensus rating and higher possible upside, equities analysts plainly believe Invacare is more favorable than Becton, Dickinson and.

Valuation and Earnings

This table compares Invacare and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Becton, Dickinson and has higher revenue and earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats Invacare on 9 of the 14 factors compared between the two stocks.

Invacare (NYSE:IVC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Invacare and Edwards Lifesciences' net margins, return on equity and return on assets.

Volatility & Risk

Invacare has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Insider and Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Invacare and Edwards Lifesciences, as provided by MarketBeat.

Invacare currently has a consensus target price of $14.00, indicating a potential upside of 41.13%. Edwards Lifesciences has a consensus target price of $90.8704, indicating a potential upside of 5.80%. Given Invacare's stronger consensus rating and higher possible upside, equities analysts plainly believe Invacare is more favorable than Edwards Lifesciences.

Valuation and Earnings

This table compares Invacare and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher revenue and earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Invacare on 10 of the 14 factors compared between the two stocks.